MF6 MagForce AG

DGAP-News: New hope for brain tumor patients in Saxony: Paracelsus Clinic Zwickau and MagForce AG open new NanoTherm therapy center for the East German region

DGAP-News: MagForce AG / Key word(s): Alliance/Miscellaneous
New hope for brain tumor patients in Saxony: Paracelsus Clinic Zwickau and MagForce AG open new NanoTherm therapy center for the East German region
05.12.2019 / 09:30
The issuer is solely responsible for the content of this announcement.


New hope for brain tumor patients in Saxony: Paracelsus Clinic Zwickau and MagForce AG open new NanoTherm therapy center for the East German region

  • Use of innovative technology in the treatment of brain tumor patients, now also in Zwickau, the central treatment center in East Germany
  • Milestone reached for the opening of the mobile NanoTherm treatment center at the Paracelsus Clinic in Zwickau

Zwickau and Berlin, Germany, December 5, 2019 - The Paracelsus Clinic in Zwickau and MagForce AG (Frankfurt, Scale, Xetra: MF6, ISIN: DE000A0HGQF5) received all necessary certifications on November 27, 2019 for the immediate use of the NanoTherm therapy system in the neurosurgery department of the Paracelsus Clinic in Zwickau, located in the German federal state of Saxony. In light of the potential life-prolonging effect of NanoTherm therapy and in the acute interest of patients, this therapeutic option is immediately available to patients in the entire Eastern region of Germany. Since the transportability of critically ill patients with glioblastoma to more distant centers was previously nearly impossible due to the limiting overall health of the patients, all brain tumor patients in this region will now also be able to benefit from the innovative therapy.

"I am glad that my team and I can now offer this highly innovative treatment option to patients with brain tumors. NanoTherm therapy means nothing less than new hope for each and every one of our patients. It complements our broad neurosurgical portfolio with a very important component," said Prof. Dr. med. habil. Jan-Peter Warnke, Senior Consultant in the Neurosurgical Clinic at the Paracelsus Clinic in Zwickau.

NanoTherm therapy is a relatively new procedure for the focal treatment of solid tumors. In the simplest of terms: Magnetic nanoparticles are introduced either directly into the tumor or into the resection cavity wall. These particles are subsequently heated by an alternating magnetic field, thus destroying the cancer cells. In June of this year, the Paracelsus Clinic Zwickau and MagForce AG entered into a cooperation agreement and announced the planned opening of a mobile NanoTherm treatment center for brain tumor patients. The successful approval of the therapy center is an important milestone.

MagForce AG was granted the European CE certificate ("European Certification") in 2011 and thus the official approval of NanoTherm therapy for the treatment of brain tumors in Germany and all member states of the European Union.

Paracelsus Clinic Saxony in Zwickau will be the fourth clinic in Europe currently to offer MagForce's NanoTherm therapy for the treatment of brain tumours. The Paracelsus Clinic in Zwickau is a standard care hospital with 180 patient beds and around 400 employees in the specialist departments of internal medicine and trauma surgery / orthopedics, general, visceral and vascular surgery, pain therapy as well as the focus disciplines of neurology and neurosurgery. The department of neurosurgery cares for approximately 2,200 patients annually and performs an average of 1,500 surgeries per year, of which approximately 300 are primary gliomas.

For more information, please visit: and

Press and investor contact information:

Paracelsus Clinic Sachsen
Isabelle Georgi
Corporate Communications & Marketing
T 037464 85-1504
M

MagForce AG
Barbara von Frankenberg
VP Communications & Investor Relations
T 7
M

Disclaimer
This release may contain forward-looking statements and information which may be identified by formulations using terms such as "expects", "aims", "anticipates", "intends", "plans", "believes", "seeks", "estimates" or "will". Such forward-looking statements are based on our current expectations and certain assumptions, which may be subject to a variety of risks and uncertainties. The results actually achieved by MagForce AG may substantially differ from these forward-looking statements. MagForce AG assumes no obligation to update these forward-looking statements or to correct them in case of developments, which differ from those, anticipated.



05.12.2019 Dissemination of a Corporate News, transmitted by DGAP - a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.

The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Archive at


Language: English
Company: MagForce AG
Max-Planck-Straße 3
12489 Berlin
Germany
Phone: +49 (0)30 308 380 0
Fax: +49 (0)30 308 380 99
E-mail:
Internet:
ISIN: DE000A0HGQF5
WKN: A0HGQF
Indices: Scale 30
Listed: Regulated Unofficial Market in Berlin, Dusseldorf, Frankfurt (Scale), Stuttgart, Tradegate Exchange
EQS News ID: 927617

 
End of News DGAP News Service

927617  05.12.2019 

fncls.ssp?fn=show_t_gif&application_id=927617&application_name=news&site_id=research_pool
EN
05/12/2019

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on MagForce AG

Sean Conroy
  • Sean Conroy

MagForce - Termination of coverage

Edison Investment Research is terminating coverage on Mercia Asset Management (MERC), Bloc Ventures (unlisted), YOC (YOC.DE), Genuit Group (GEN), AlzeCure Pharma (ALZCUR), abrdn Latin American Income Fund (ALAI), Magforce (MF6), OPG Power Ventures (OPG) and paragon (PGN). Please note you should no longer rely on any previous research or estimates for this company. All forecasts should now be considered redundant.

Cosmin Filker
  • Cosmin Filker

Research Comment englisch - MagForce AG - 27.07.22

MagForce AG unexpectedly files for insolvency; price target and rating, suspended In an announcement dated 26.07.2022, MagForce AG informed the capital market, to our, complete surprise, that it intends to file for insolvency proceedings due to insolvency. According to the company's announcement, this had become necessary after reorganisationmeasures had not led to the desired cost savings. Even though the company has not yet been able to generate any significant cash inflows from its operatin...

Cosmin Filker
  • Cosmin Filker

Research Comment - MagForce AG - 27.07.22

MagForce AG meldet überraschend Insolvenz an; Kursziel und Rating ausgesetzt Mit Meldung vom 26.07.2022 hat die MagForce AG den Kapitalmarkt, für uns komplett überraschend, darüber informiert, einen Antrag auf Eröffnung eines Insolvenzverfahrens wegen Zahlungsunfähigkeit stellen zu wollen. Gemäß Unternehmensmeldung sei dies notwendig geworden, nachdem reorganisatorische Maßnahmen nicht zu den gewünschten Kosteneinsparungen geführt haben. Auch wenn die Gesellschaft aufgrund der noch nicht erfol...

Cosmin Filker
  • Cosmin Filker

Investment im Fokus - MagForce AG - 18.07.22

Die MagForce AG mit Sitz in Berlin ist nach eigenen Angaben ein führendes Unternehmen auf dem Gebiet der Nanomedizin mit Fokus auf der Krebstherapie. Die von ihr entwickelte NanoTherm® Therapie wäre nach Unternehmensangaben für die lokale Behandlung von nahezu allen soliden Tumoren geeignet. Die Behandlung erfolgt durch Wärme, die mittels Aktivierung von injizierten superparamagnetischen Nanopartikeln erzeugt wird. Die Bestandteile dieser Therapie, die Medizinprodukte NanoTherm®, NanoPlan®, Ther...

Cosmin Filker ... (+2)
  • Cosmin Filker
  • Marcel Goldmann

Research Report (Anno) englisch - MagForce AG - 13.07.22

By its own account, MagForce AG, with its registered office in Berlin, is a leading company in the field of nanomedicine with a focus on cancer treatment. The NanoTherm® treatment developed by the company could be suitable for the local treatment of almost all solid tumours. The treatment is based on heat that is created by the activation of injected superparamagnetic nanoparticles. The components of this treatment, the medical devices NanoTherm® and NanoPlan® and the thermometric catheter TK01 ...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch